Chia-Ling Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chia-Ling Wu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
An-Hsun Chou
Department of Anesthesiology, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan, Taiwan
1 shared publicationChia-Pin Lin
Department of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan, Taiwan
1 shared publicationChun-Yu Chen
Department of Anesthesiology, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan, Taiwan
1 shared publication- Feng-Cheng Chang
Department of Anesthesiology, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan City, Taiwan
1 shared publication Fu-Chih Hsiao
Department of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan, Taiwan
1 shared publication- Shao-Wei Chen
Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan City, Taiwan; Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan City, Taiwan
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 19, 1-12
Heart Failure Pharmacotherapy and Long-Term Outcomes After Extracorporeal Membrane Oxygenation: A Nationwide Real-World Cohort Study
Objective: We examined prescription trends and associations between post-discharge heart failure (HF) guideline-directed medical therapy (GDMT) and long-term outcomes in patients with cardiogenic extracorporeal membrane oxygenation (ECMO), a population with limited evidence on long-term management. Methods: This nationwide retrospective observational cohort used Taiwan’s real-world National Health Insurance Research Database. Adults undergoing cardiogenic ECMO during 2011– 2023 who survived at least 6 months after discharge were included. Qualifying exposure required at least 28 cumulative prescription days during the first 6 months after discharge. Follow-up began at the 6-month landmark and continued through December 31, 2024. Associations were estimated using stabilized inverse probability of treatment weighting; propensity score matching served as a sensitivity analysis. Results: Among 4,428 patients, 3,164 received qualifying HF pharmacotherapy and 1,264 did not. Use shifted from angiotensin-converting enzyme inhibitors and digoxin toward angiotensin receptor blockers, beta-blockers, sodium-glucose cotransporter 2 inhibitors, and ivabradine. HF medication use was associated with lower all-cause mortality (HR, 0.57; 95% CI, 0.51– 0.65), the composite of cardiovascular death or HF hospitalization (HR, 0.77; 95% CI, 0.65– 0.92), and cardiovascular death (HR, 0.65; 95% CI, 0.53– 0.79). Renin-angiotensin system inhibitors and beta-blockers were each associated with lower mortality (HR, 0.69; 95% CI, 0.61– 0.78). Sensitivity analyses were consistent. Conclusion: Among 6-month survivors of cardiogenic ECMO, a high-risk and clinically unique population often excluded from HF trials, post-discharge HF pharmacotherapy was associated with lower long-term mortality. These findings support structured cardiovascular reassessment and individualized HF medication review after ECMO.
- 1 September 2026
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 19, 1-12
Open AccessHeart Failure Pharmacotherapy and Long-Term Outcomes After Extracorporeal Membrane Oxygenation: A Nationwide Real-World Cohort Study
Objective: We examined prescription trends and associations between post-discharge heart failure (HF) guideline-directed medical therapy (GDMT) and long-term outcomes in patients with cardiogenic extracorporeal membrane oxygenation (ECMO), a population with limited evidence on long-term management. Methods: This nationwide retrospective observational cohort used Taiwan’s real-world National Health Insurance Research Database. Adults undergoing cardiogenic ECMO during 2011– 2023 who survived at least 6 months after discharge were included. Qualifying exposure required at least 28 cumulative prescription days during the first 6 months after discharge. Follow-up began at the 6-month landmark and continued through December 31, 2024. Associations were estimated using stabilized inverse probability of treatment weighting; propensity score matching served as a sensitivity analysis. Results: Among 4,428 patients, 3,164 received qualifying HF pharmacotherapy and 1,264 did not. Use shifted from angiotensin-converting enzyme inhibitors and digoxin toward angiotensin receptor blockers, beta-blockers, sodium-glucose cotransporter 2 inhibitors, and ivabradine. HF medication use was associated with lower all-cause mortality (HR, 0.57; 95% CI, 0.51– 0.65), the composite of cardiovascular death or HF hospitalization (HR, 0.77; 95% CI, 0.65– 0.92), and cardiovascular death (HR, 0.65; 95% CI, 0.53– 0.79). Renin-angiotensin system inhibitors and beta-blockers were each associated with lower mortality (HR, 0.69; 95% CI, 0.61– 0.78). Sensitivity analyses were consistent. Conclusion: Among 6-month survivors of cardiogenic ECMO, a high-risk and clinically unique population often excluded from HF trials, post-discharge HF pharmacotherapy was associated with lower long-term mortality. These findings support structured cardiovascular reassessment and individualized HF medication review after ECMO.